Helping patients with rare genetic disorders of obesity
 

The Genetic Obesity Project is dedicated to improving the understanding, diagnosis, and treatment of severe obesity that is caused by specific genetic defects–particularly rare genetic disorders that result in life-threatening obesity.

LEARN MORE >

Patient Stories
Single genetic defects along the MC4 pathway that result in early-onset, severe obesity are now identified.

PATIENT STORIES >

Learn about the Genetic Obesity-ID (GO-ID) Initiative
I am a Healthcare Provider
I am a Patient or Caregiver
Select to get started
This program is supported by Rhythm, a Boston-based biopharmaceutical company developing the MC4R peptide agonist, setmelanotide (RM-493), for obesity caused by genetic deficiencies in the MC4 pathway.
Back to Top